**Table 2 (Part 1). The outcomes in lung cancer patients among the included studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Median OS times** | | **p-value** | **Survival rates, mortality** | | **p-value** | **Multivariate analysis** | | | |
| NN patients | HN patients | NN patients | HN patients |  | HR | 95% CI | p-value |
| **Yongping Yang et al. (2017)27** | 1.1±0.42 year | 0.83±0.35 year | <0.05 | 62.26%  1-year SR  1.89% 5-year SR | 30.36% 1-year SR  0% 5-year SR | 0.045  0.15 | NR | - | - | - |
| **Kell Osterlind et al. (1987)28** | NR | NR | - | NR | NR | - | NR | - | - | - |
| **Maja Zarzecka et al. (2014)29** | NR | NR | - | 7.8% mortality | 28.7% mortality | 0.0001 | NR | - | - | - |
| **Andreas Hermes et al. (2012)30** | 13 months | 9 months | <0.001 | NR | NR | - | I | - | - | 0.025 LD 0.038 ED |
| **Wenxian Wang et al. (2016)31** | 14.5 months | 11.4 months | <0.001 | NR | NR | - | I | 1.82 | 1.34-2.47 | 0.007 |
| **Rossana Berardi et al. (2017)32** | 15.5 months | 8.78 months | <0.001 | 57.06% SR | 33.33% SR | 0.19 | I | 1.59 | 1.14-2.21 | 0.006 |
| **Amitabha Sengupta et al. (2013)33** | NR | NR | - | NR | NR | - | N.I. | - | - | NS |
| **Naohiro Kobayashi et al. (2014)34** | NR | NR | - | 74.8% 5-year SR | 59.7% 5-year SR | 0.002 | I | 1.53 | 1.005-2.322 | 0.047 |
| **Giovanni Fucá et al. (2018)35** | 11.6 months | 2.8 months | <0.001 | 39.76% SR at 10 months | 15.38% SR at 10 months | - | I | 3.11 | 1.91-5.05 | <0.001 |
| **Omer S. Alamoudi (2010)36** | NR | NR | - | NR | NR | - | NR | - | - | - |
| **Olfred Hansen et al. (2010)37** | 11.2 months | 7.1 months | 0.0001 | 57.25% SR at 10 months | 27.27% SR at 10 months | - | I | 1.6 | 1.27-2.01 | <0.001 |
| **Martin Svaton et al. (2014)38** | 10.9 months | 4.6 months | <0.001 | 54.33% SR at 10 months | 21.36% SR at 10 months | <0.001 | I | 1.87 | 1.47-2.39 | <0.001 |

**Abbreviations**: OS- overall survival; NN- normonatremic; HN- hyponatremic; NR- Not reported; S-significant; NS- not significant; I- Independent factor; N.I.- Not independent factor; HR- hazard ratio; RR- risk ratio; SR- Survival rate; CI- confidence interval; LD- Limited Disease; ED- Extensive Disease

**Table 2 (Part 2). The outcomes in lung cancer patients among the included studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Median OS times** | | **p-value** | **Survival rates, mortality** | | **p-value** | **Outcome in multivariate analysis** | | | |
| NN patients | HN patients | NN patients | HN patients |  | HR | 95% CI | p-value |
| **Simon G. Allan et al. (1990)39** | 7 months | 7months | 0.06 | NR | NR | - | N.I. | - | - | NS |
| **Wei Li et al. (2019)40** | NR | NR | - | 79.6% SR at 25 months | 73.83% SR at 25 months | - | NR | - | - | - |
| **Kell Osterlind et al. (1986)41** | 40 weeks | 34 weeks | - | NR | NR | - | I | - | - | <0.05 |
| **Kartik H. Doshi et al. (2016)42** | 16 months | 11 months | <0.05 | 61.31% SR at 10 months | 54.16% SR at 10 months | - | I | 2.07 | 1.11–3.84 | <0.05 |
| **Bruce Johnson et al. (1997)43** | NR | NR | - | NR | NR | - | N.I. | - | - | NS |
| **U.Sagman et al. (1991)44** | 45 weeks | 42 weeks | 0.006 | NR | NR | - | N.I. | - | - | NS |
| **W. Jacot et al. (2008)45** | 18.7 months | 4.1 months | <0.0001 | NR | NR | - | I | 1.99 | 1.04–3.77 | S |
| **Xuan Hong et al. (2016)46** | 11.7 months | 10 months | 0.039 | 59.48% SR at 10 months | 49.69% SR at 10 months | - | N.I. | - | - | NS |
| **I. Maestu et al. (1997)47** | NR | NR | - | NR | NR | - | N.I. | - | - | NS |
| **Masaaki Kawahara et al. (1997)48** | 11.4 months | 9.1 months | 0.0072 | NR | NR | - | N.I. | - | - | NS |
| **T.Cerny et al. (1987)49** | NR | NR | - | 59.48% SR at 10 months | 34% SR at 10 months | - | I | - | - | 0.0009 |
| **MA Fang et al. (2011)50** | 14.1 months | 7.6 months | <0.001 | 81.31% SR at 10 months | 32.83% SR at 10 months | - | NR | - | - | - |
| **Shigeki Umemura et al. (2007)51** | 10.6 months | 10 months | 0.6653 | 50% SR at 10 months | 51.77% SR at 10 months | NS | N.I. | - | - | NS |

**Abbreviations:** OS- overall survival; NN- normonatremic; HN- hyponatremic; NR- Not reported; S-significant; NS- not significant; I- Independent factor; N.I.- Not independent factor; HR- hazard ratio; RR- risk ratio; SR- Survival rate; CI- confidence interval